Physician profile
David R Jackson
NPI 1215079983
$1,922.62
in general payments reported to CMS, 2019-2025
34 companies · $307 in 2025
The $307 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $754 · 2022: $447 · 2023: $240 · 2024: $175 · 2025: $307.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $722.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $721.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $190.45 | 2021-2023 | Rybelsus, Ozempic |
| Pfizer INC. | $188.54 | 2021-2024 | |
| Abbvie INC. | $156.75 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $119.68 | 2021-2023 | Farxiga, Fasenra |
| Paratek Pharmaceuticals, INC. | $103.61 | 2023-2024 | Nuzyra |
| Astellas Pharma US INC | $99.99 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $94.43 | 2025 | Caplyta |
| Novartis Pharmaceuticals Corporation | $87.34 | 2021 | |
| Sunovion Pharmaceuticals INC. | $84.85 | 2021-2022 | |
| Exact Sciences Corporation | $82.19 | 2025 | The Cologuard Plus Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $65.97 | 2022-2025 | |
| Collegium Pharmaceutical, INC. | $53.88 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $48.30 | 2022-2023 | Xifaxan |
| Almatica Pharma LLC | $45.85 | 2022 | |
| Lilly USA, LLC | $45.84 | 2021-2024 | Mounjaro, Zepbound |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scilex Pharmaceuticals INC. | $42.51 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $37.69 | 2024 | Eliquis |
| Kowa Pharmaceuticals America, INC. | $32.85 | 2021 | |
| Merck Sharp & Dohme LLC | $32.38 | 2021 | |
| Ferring Pharmaceuticals INC. | $31.71 | 2022 | |
| Janssen Pharmaceuticals, INC | $31.13 | 2021-2022 | |
| Philips North America LLC | $29.62 | 2024 | (Ck7) Extended Holter |
| Convatec INC. | $25.05 | 2023 | |
| Abbott Laboratories | $23.90 | 2021 | |
| Organogenesis INC. | $22.81 | 2023 | Puraply |
| Smith+Nephew, INC. | $19.42 | 2024 | Collagenase Santyl |
| Axsome Therapeutics, INC. | $18.76 | 2025 | Auvelity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.56 | 2021 | |
| Eisai INC. | $16.56 | 2021 | |
| Phathom Pharmaceuticals, INC. | $15.75 | 2025 | Voquezna |
| Dexcom, INC. | $15.42 | 2021 | |
| Glaxosmithkline, LLC. | $14.71 | 2022 | |
| Amgen INC. | $14.30 | 2022 | |
| Pacira Pharmaceuticals Incorporated | $12.82 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Jackson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.